These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 36209275)
1. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. Su X; Xie Y; Zhang J; Li M; Zhang Q; Jin G; Liu F Cell Death Dis; 2022 Oct; 13(10):861. PubMed ID: 36209275 [TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease. Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538 [TBL] [Abstract][Full Text] [Related]
3. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900 [TBL] [Abstract][Full Text] [Related]
4. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis. Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971 [TBL] [Abstract][Full Text] [Related]
5. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men. Mäkinen S; Sree S; Ala-Nisula T; Kultalahti H; Koivunen P; Koistinen HA Diabetologia; 2024 Sep; 67(9):1943-1954. PubMed ID: 38814443 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells. Bordji K; Grandval A; Cuhna-Alves L; Lechapt-Zalcman E; Bernaudin M FEBS J; 2014 Dec; 281(23):5220-36. PubMed ID: 25244496 [TBL] [Abstract][Full Text] [Related]
7. [HIF-ɑ: New Target For Treatment of Renal Anemia. Molecular Aspects and Activation of Pathway HREs]. Mazza F; Cicciarelli A; Rubino F; Apponi F; Cioffi EA; Simonelli R G Ital Nefrol; 2024 Jun; 41(3):. PubMed ID: 38943324 [TBL] [Abstract][Full Text] [Related]
10. Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. Zhao W; Yun K Exp Cell Res; 2022 Sep; 418(2):113277. PubMed ID: 35810776 [TBL] [Abstract][Full Text] [Related]
11. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action. Chang WT; Lo YC; Gao ZH; Wu SN Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416 [TBL] [Abstract][Full Text] [Related]
12. Get use to the -dustats: Roxadustat and molidustat, members of the hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor drug class promote kidney function, perfusion and oxygenation in rats through nitric oxide. Jensen BL Acta Physiol (Oxf); 2021 Sep; 233(1):e13706. PubMed ID: 34143560 [No Abstract] [Full Text] [Related]
13. Prolyl-4-hydroxylase 2 enhances hypoxia-induced glioblastoma cell death by regulating the gene expression of hypoxia-inducible factor-α. Sun W; Jelkmann W; Depping R Cell Death Dis; 2014 Jul; 5(7):e1322. PubMed ID: 25010988 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats. Beck J; Henschel C; Chou J; Lin A; Del Balzo U Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological induction of the hypoxia response pathway in Huh7 hepatoma cells limits proliferation but increases resilience under metabolic stress. Jacquemin C; El Orch W; Diaz O; Lalande A; Aublin-Gex A; Jacolin F; Toesca J; Si-Tahar M; Mathieu C; Lotteau V; Perrin-Cocon L; Vidalain PO Cell Mol Life Sci; 2024 Jul; 81(1):320. PubMed ID: 39078527 [TBL] [Abstract][Full Text] [Related]
16. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220 [TBL] [Abstract][Full Text] [Related]
17. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3 Li X; Zou Y; Xing J; Fu YY; Wang KY; Wan PZ; Zhai XY Oxid Med Cell Longev; 2020; 2020():6286984. PubMed ID: 32051732 [TBL] [Abstract][Full Text] [Related]
18. The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A. Ike T; Doi S; Nakashima A; Sasaki K; Ishiuchi N; Asano T; Masaki T Am J Physiol Renal Physiol; 2022 Nov; 323(5):F539-F552. PubMed ID: 36074918 [TBL] [Abstract][Full Text] [Related]
19. Correction: HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. Su X; Xie Y; Zhang J; Li M; Zhang Q; Jin G; Liu F Cell Death Dis; 2023 Jan; 14(1):31. PubMed ID: 36650128 [No Abstract] [Full Text] [Related]
20. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Henze AT; Riedel J; Diem T; Wenner J; Flamme I; Pouyseggur J; Plate KH; Acker T Cancer Res; 2010 Jan; 70(1):357-66. PubMed ID: 20028863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]